Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases

References

1. WHO. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/. 2018.

   View in Article

   • Google Scholar
2. • Houben R.M.
   • Dodd P.J.
   The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.
   PLoS Med. 2016 25; 13e1002152
   View in Article

   • Google Scholar
3. • Goletti D.
   • Petrone L.
   • Ippolito G.
   • Niccoli L.
   • Nannini C.
   • Cantini F.
   Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
   Expert Rev Anti Infect Ther. 2018; 16: 501-512
   View in Article

   • Google Scholar
4. • Cantini F.
   • Nannini C.
   • Niccoli L.
   • Petrone L.
   • Ippolito G.
   • Goletti D.
   risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted Biologics.
   Mediators Inflamm. 2017; 20178909834
   View in Article

   • Google Scholar
5. • Cantini F.
   • Niccoli L.
   • Goletti D.
   Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries.
   J Rheumatol Suppl. 2014; 91: 56-64
   View in Article

   • Google Scholar
6. • Baddley J.W.
   • Cantini F.
   • Goletti D.
   • Gomez-Reino J.J.
   • Mylonakis E.
   • San-Juan R.
   • et al.
   ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents).
   Clin Microbiol Infect. 2018; 24: S10-S20
   View in Article

   • Google Scholar
7. • Cantini F.
   • Nannini C.
   • Niccoli L.
   • Iannone F.
   • Delogu G.
   • Garlaschi G.
   • et al.
   Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
   Autoimmun Rev. 2015; 14: 503-509
   View in Article

   • Google Scholar
8. • Goletti D.
   • Carrara S.
   • Vincenti D.
   • Saltini C.
   • Rizzi E.B.
   • Schinina V.
   • et al.
   Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study.
   Clin Microbiol Infect. 2006; 12: 544-550
   View in Article

   • Google Scholar
9. • Goletti D.
   • Carrara S.
   • Butera O.
   • Amicosante M.
   • Ernst M.
   • Sauzullo I.
   • et al.
   Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study.
   PLoS One. 2008; 3: e3417
   View in Article

   • Google Scholar
10. • Goletti D.
    • Lee M.R.
    • Wang J.Y.
    • Walter N.
    • Ottenhoff T.H.M.
    Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease.
    Respirology. 2018; 23: 455-466
    View in Article

    • Google Scholar
11. • Abubakar I.
    • Drobniewski F.
    • Southern J.
    • Sitch A.J.
    • Jackson C.
    • Lipman M.
    • et al.
    Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study.
    Lancet Infect Dis. 2018; 18: 1077-1087
    View in Article

    • Google Scholar
12. • Kik S.V.
    • Schumacher S.
    • Maria Cirillo D.
    • Churchyard G.
    • Boehme C.
    • Goletti D.
    • et al.
    An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.
    Eur Respir J. 2018; 52 (pii: 1800946)https://doi.org/10.1183/13993003.00946-2018
    View in Article

    • Google Scholar
13. • Riou C.
    • Tanko R.F.
    • Soares A.P.
    • Masson L.
    • Werner L.
    • Garrett N.J.
    • et al.
    Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype.
    J Immunol. 2015; 195: 2273-2281
    View in Article

    • Google Scholar
14. • Chiacchio T.
    • Petruccioli E.
    • Vanini V.
    • Cuzzi G.
    • La Manna M.P.
    • Orlando V.
    • et al.
    Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects.
    Immunol Lett. 2018; 198: 33-43
    View in Article

    • Google Scholar
15. • Chiacchio T.
    • Petruccioli E.
    • Vanini V.
    • Cuzzi G.
    • Pinnetti C.
    • Sampaolesi A.
    • et al.
    Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients.
    J Infect. 2014; 69: 533-545
    View in Article

    • Google Scholar
16. • Barcellini L.
    • Borroni E.
    • Brown J.
    • Brunetti E.
    • Campisi D.
    • Castellotti P.F.
    • et al.
    First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.
    Eur Respir J. 2016; 48: 1411-1419
    View in Article

    • Google Scholar
17. • Petruccioli E.
    • Chiacchio T.
    • Pepponi I.
    • Vanini V.
    • Urso R.
    • Cuzzi G.
    • et al.
    First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus.
    J Infect. 2016; 73: 588-597
    View in Article

    • Google Scholar
18. • Petruccioli E.
    • Vanini V.
    • Chiacchio T.
    • Cuzzi G.
    • Cirillo D.M.
    • Palmieri F.
    • et al.
    Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.
    Tuberculosis (Edinb). 2017; 106: 38-43
    View in Article

    • Google Scholar
19. • Day C.L.
    • Abrahams D.A.
    • Lerumo L.
    • Janse van Rensburg E.
    • Stone L.
    • O'rie T.
    • et al.
    Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load.
    J Immunol. 2011; 187: 2222-2232
    View in Article

    • Google Scholar
20. • Sauzullo I.
    • Mengoni F.
    • Mascia C.
    • Pavone P.
    • Savelloni G.
    • Massetti A.P.
    • et al.
    Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis.
    Med Microbiol Immunol. 2019; 208: 171-183
    View in Article

    • Google Scholar
21. • Petrone L.
    • Vanini V.
    • Chiacchio T.
    • Petruccioli E.
    • Cuzzi G.
    • Schinina V.
    • et al.
    Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection.
    Tuberculosis (Edinb). 2018; 111: 147-153
    View in Article

    • Google Scholar
22. • Goletti D.
    • Lindestam Arlehamn C.S.
    • Scriba T.J.
    • Anthony R.
    • Cirillo D.M.
    • Alonzi T.
    • et al.
    Can we predict tuberculosis cure? What tools are available?.
    Eur Respir J. 2018; 52 (Print 2018 Nov)https://doi.org/10.1183/13993003.01089-2018
    View in Article

    • Google Scholar
23. • Igari H.
    • Ishikawa S.
    • Nakazawa T.
    • Oya Y.
    • Futami H.
    • Tsuyuzaki M.
    • et al.
    Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis.
    J Infect Chemother. 2018; 24: 110-116
    View in Article

    • Google Scholar
24. • Minozzi S.
    • Bonovas S.
    • Lytras T.
    • Pecoraro V.
    • Gonzalez-Lorenzo M.
    • Bastiampillai A.J.
    • et al.
    Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Expert Opin Drug Saf. 2016; 15: 11-34
    View in Article

    • Google Scholar
25. • Petruccioli E.
    • Chiacchio T.
    • Vanini V.
    • Cuzzi G.
    • Codecasa L.R.
    • Ferrarese M.
    • et al.
    Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection.
    Sci Rep. 2018; 8 (15626-018-33825-w)
    View in Article

    • Google Scholar
26. • Sauzullo I.
    • Scrivo R.
    • Sessa P.
    • Mengoni F.
    • Vullo V.
    • Valesini G.
    • et al.
    Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.
    Sci Rep. 2018; 8 (7881-018-26097-x)
    View in Article

    • Google Scholar
27. • Pieterman E.D.
    • Liqui Lung F.G.
    • Verbon A.
    • Bax H.I.
    • Ang C.W.
    • Berkhout J.
    • et al.
    A multicentre verification study of the QuantiFERON((R))-TB Gold Plus assay.
    Tuberculosis (Edinb). 2018; 108: 136-142
    View in Article

    • Google Scholar
28. • Nemes E.
    • Rozot V.
    • Geldenhuys H.
    • Bilek N.
    • Mabwe S.
    • Abrahams D.
    • et al.
    Optimization and interpretation of serial QuantiFERON testing to measure acquisition of mycobacterium tuberculosis infection.
    Am J Respir Crit Care Med. 2017; 196: 638-648
    View in Article

    • Google Scholar
29. • Uzorka J.W.
    • Kroft L.J.M.
    • Bakker J.A.
    • van Zwet E.W.
    • Huisman E.
    • Knetsch-Prins C.
    • et al.
    Proof of concept that most borderline Quantiferon results are true antigen-specific responses.
    Eur Respir J. 2017; 50 (Print 2017 Nov)https://doi.org/10.1183/13993003.01630-2017
    View in Article

    • Google Scholar
30. • Uzorka J.W.
    • Delfos N.M.
    • Witte A.M.C.
    • Scheper H.
    • van Soolingen D.
    • Arend S.M.
    Tuberculosis after a borderline QuantiFERON result during screening before infliximab.
    Eur Respir J. 2018; 52 (Print 2018 Aug)https://doi.org/10.1183/13993003.00913-2018
    View in Article

    • Google Scholar
31. • de Paus R.A.
    • van Meijgaarden K.E.
    • Prins C.
    • Kamphorst M.H.
    • Arend S.M.
    • Ottenhoff T.H.M.
    • et al.
    Immunological characterization of latent tuberculosis infection in a low endemic country.
    Tuberculosis (Edinb). 2017; 106: 62-72
    View in Article

    • Google Scholar
32. • Leyten E.M.
    • Arend S.M.
    • Prins C.
    • Cobelens F.G.
    • Ottenhoff T.H.
    • van Dissel J.T.
    Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation.
    Clin Vaccine Immunol. 2007; 14: 880-885
    View in Article

    • Google Scholar
33. • Butera O.
    • Chiacchio T.
    • Carrara S.
    • Casetti R.
    • Vanini V.
    • Meraviglia S.
    • et al.
    New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response.
    BMC Infect Dis. 2009; 9 (182-2334-9-182)
    View in Article

    • Google Scholar
34. • Grzybowsky S.
    Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service.
    Am Rev Respir Dis. 1971; 104: 605-608
    View in Article

    • Google Scholar
35. • Goletti D.
    • Sanduzzi A.
    • Delogu G.
    Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches.
    J Rheumatol Suppl. 2014; 91: 24-31
    View in Article

    • Google Scholar
36. • Goletti D.
    • Petrone L.
    • Ippolito G.
    • Niccoli L.
    • Nannini C.
    • Cantini F.
    Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Expert Rev Anti Infect Ther. 2018; 16: 501-512
    View in Article

    • Google Scholar
37. • Wong S.H.
    • Gao Q.
    • Tsoi K.K.
    • Wu W.K.
    • Tam L.S.
    • Lee N.
    • et al.
    Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis.
    Thorax. 2016; 71: 64-72
    View in Article

    • Google Scholar